Joel S. Lippman, M.D. v. Ethicon, Inc. (073324)

119 A.3d 215, 222 N.J. 362, 40 I.E.R. Cas. (BNA) 650, 2015 N.J. LEXIS 791
Supreme Court of New Jersey·Decided July 15, 2015·No. A-65/66-13·Published·Cited by 88 cases

Opinion

*365 Justice LaVECCHIA

delivered the opinion of the Court.

Cross-petitions for certification were granted in this matter to address issues related to the application of the Conscientious Employee Protection Act (CEPA or Act), N.J.S.A. 34:19-1 to -14, to so-called “watchdog” employees. More specifically, both petitions concern whether an employee, whose job duties entail knowing or securing compliance with a relevant standard of care and knowing when an employer’s actions or proposed actions deviate from that standard of care, may invoke the whistleblower protections afforded under N.J.S.A. 34:19-3 of CEPA.

Plaintiffs normal job duties included providing his medical opinion about the safety of defendant pharmaceutical company’s products. After he was terminated from his high-level position with the corporation, he filed this CEPA action claiming that his employer retaliated against him. The trial court granted defendants’ motion for summary judgment on the ground that plaintiffs performance of his regular job duties could not constitute CEPAproteeted conduct. The Appellate Division reversed, concluding that watchdog employees are among those most in need of CEPA’s protection, and that the plain language of the statute does not exempt from protection conduct that constitutes a job duty. Lippman v. Ethicon, Inc., 432 N.J.Super. 378, 406-08, 75 A.3d 432 (App.Div.2013). In so holding, the panel also articulated a tailored standard for evaluating CEPA claims asserted by watchdog employees. Id. at 410, 75 A.3d 432.

According to plaintiff, the Appellate Division’s standard, in effect, raised the bar for the proof that such employees must present in order to establish a prima facie CEPA claim because it requires demonstration that the employee either refused to participate in the objectionable conduct or pursued and exhausted all internal means of securing compliance. Plaintiffs petition focuses on whether the Appellate Division improperly added an element to his CEPA-authorized cause of action, thereby subjecting watchdog employees to a different and heightened burden compared to other CEPA plaintiffs. Defendants’ petition allows this Court to *366 review the Appellate Division’s published decision holding that performance of job duties by a watchdog employee may constitute CEPA-proteeted activity.

For the reasons that follow, we affirm the Appellate Division’s judgment that CEPA’s protections extend to the performance of regular job duties 1 by watchdog employees. In so holding, we disapprove of the standard that the panel articulated for assessing claims by such employees. The panel’s attempt to add clarity to the assessment of claims by such plaintiffs impermissibly results in adding to the burden for this subset of CEPA plaintiffs. By its very terms, the statutory cause of action created by CEPA applies equally to all employees. There is no evidence of legislative intent to have the Act operate any other way. Accordingly, we hold that there can be no additional burden imposed on watchdog employees seeking CEPA protection, unless and until the Legislature expresses its intent to differentiate among the classes of employees who are entitled to CEPA protection.

I.

A.

This matter arose upon the filing of plaintiffs complaint in the Law Division against Ethicon, Inc. (Ethicon) and Johnson & Johnson, Inc. (J & J) (collectively defendants), alleging CEPA violations under N.J.S.A. 34:19-3(a) and (c). Plaintiff Joel S. Lippman, M.D., 2 alleged in his complaint, among other claims, that his employment was terminated due to his whistleblowing activities, which plaintiff identified as his actions in reporting a number of products as dangerous and in violation of the federal Food, *367 Drug and Cosmetic Act, 21 U.S.C.A. §§ 301-399Í, and advising that defendants either recall the products or perform further research. 3 This appeal comes to us on a summary judgment record; accordingly, we review the facts in the light most favorable to plaintiff, the non-moving party in this matter. Brill v. Guardian Life Ins. Co. of Am., 142 N.J. 520, 523, 540, 666 A.2d 146 (1995). The facts are set forth below as presented by the parties and as described by the Appellate Division, Lippman, supra, 432 N.J.Super. at 382-405, 75 A.3d 432.

Plaintiff was employed at Ethicon, a manufacturer of medical devices used for surgical procedures, from July 2000 until his termination. Prior to his work at Ethicon, he worked from 1990 to 2000 at Ortho-McNeil Pharmaceutical (OMP), as director of medical services and then vice president of clinical trials. Both Ethicon and OMP are subsidiaries of J & J.

Initially plaintiff served at Ethicon as vice president of medical affairs. In 2002, he was promoted to worldwide vice president of medical affairs and chief medical officer of Ethicon. His direct superior and the person to whom he reported at Ethicon was Dennis Longstreet, the company group chairperson. Longstreet reported to Michael J. Dormer, J & J’s chairperson for the medical devices and diagnostic group. In 2005, Sherilyn S. McCoy replaced Longstreet as Ethicon’s company group chairperson.

As vice president of medical affairs, “plaintiff was ‘responsible for safety, ensuring that safe medical practices occurred in clinical trials of [Ethicon’s] products; ... medical reviews, information from a medical standpoint; [and] medical writing.’ ” Lippman, supra, 432 N.J.Super. at 388, 75 A.3d 432 (alterations in original). Consistent with those responsibilities, plaintiff served on multiple internal review boards for Ethicon. Generally stated, those *368 boards addressed strategic product activities and evaluated the health and safety risks of products. As a member of those boards, plaintiffs function was to provide medical and clinical expertise and opinions. Id. at 388-90, 75 A.3d 432. In short, Lippman was part of Ethicon’s high-level policy decision making.

Of particular relevance in this matter, plaintiff was a member of a quality board that “was created to assess the health risks posed by Ethicon’s products and to provide ‘medical input’ in determining whether the company needed to take corrective measures with respect to their products in the field.” Id. at 389, 75 A.3d 432. At times, recall of a product would become “necessary to conform to the requirements of the particular regulatory agency with jurisdiction, internal policy directives, and/or to protect the health and safety of the patient[s].” Ibid.

Free access — add to your briefcase to read the full text and ask questions with AI

Joel S. Lippman, M.D. v. Ethicon, Inc. (073324), 119 A.3d 215, 222 N.J. 362, 40 I.E.R. Cas. (BNA) 650, 2015 N.J. LEXIS 791 (N.J. 2015).

119 A.3d 215 (Joel S. Lippman, M.D. v. Ethicon, Inc. (073324)) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Ladawn Chapman v. Alaris Health, LLC
New Jersey Superior Court App Division, 2025
James Warnet v. Borough of Bergenfield
New Jersey Superior Court App Division, 2025
Edward Costello v. Myron Corp.
New Jersey Superior Court App Division, 2025
Michael Coe v. Trenton Board of Education
New Jersey Superior Court App Division, 2025
Sheena Jones v. the Mentor Network
New Jersey Superior Court App Division, 2025
Michael Hand v. Borough of New Providence
New Jersey Superior Court App Division, 2025
Helen Ford v. Ronald P. Edwards
New Jersey Superior Court App Division, 2025
Kevin Noah v. Sparta Township Board of Education
New Jersey Superior Court App Division, 2024
Anna-Maria Obiedzinski v. Township of Tewksbury
New Jersey Superior Court App Division, 2024
Joshua Cummis v. Township of Maplewood
New Jersey Superior Court App Division, 2024
William Fulmore v. City of Englewood
New Jersey Superior Court App Division, 2024
Roxana Gaviria v. Board of Education of the City of Elizabeth
New Jersey Superior Court App Division, 2024